IgG1 Allotypes Influence the Pharmacokinetics of Therapeutic Monoclonal Antibodies through FcRn Binding
- 15 January 2016
- journal article
- research article
- Published by The American Association of Immunologists in The Journal of Immunology
- Vol. 196 (2), 607-613
- https://doi.org/10.4049/jimmunol.1501780
Abstract
Because IgG1 allotypes might have different half-lives, their influence on infliximab (G1m17,1 allotype) pharmacokinetics was investigated in a group of spondyloarthritis patients. Infliximab was found to have a shorter half-life in patients homozygous for the G1m17,1 allotypes than in those carrying the G1m3 with no G1m1 (G1m3,-1) allotype. Because the neonatal FcR (FcRn) is involved in the pharmacokinetics of mAbs, the interaction of different IgG1 allotypes with FcRn was examined using cellular assays and surface plasmon resonance. G1m17,1 mAbs, such as infliximab and rituximab, were shown to bind more efficiently to FcRn and to be transcytosed better than the G1m3,-1 mAb cetuximab, which explains why infliximab is a better competitor for endogenous IgG1 in G1m3,-1 allotype–bearing patients. A set of four allotype variants of adalimumab (G1m17,1; G1m17,-1; G1m3,1; and G1m3,-1) was also tested for its binding to FcRn, revealing that the G1m3,1 variant, not present in commercial mAbs, binds more efficiently to FcRn and is transcytosed better than the other three variants, all of which are found in therapeutic mAbs.Keywords
This publication has 49 references indexed in Scilit:
- Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patientsBlood, 2012
- Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptorNature Communications, 2012
- Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potentialNature Communications, 2011
- Neonatal Fc receptor and IgG-based therapeuticsmAbs, 2011
- Population Pharmacokinetics of Therapeutic Monoclonal AntibodiesClinical Pharmacokinetics, 2010
- Enhanced antibody half-life improves in vivo activityNature Biotechnology, 2010
- An Enzyme-Linked Immunosorbent Assay for Therapeutic Drug Monitoring of InfliximabTherapeutic Drug Monitoring, 2006
- The Major Histocompatibility Complex–related Fc Receptor for IgG (FcRn) Binds Albumin and Prolongs Its LifespanThe Journal of Experimental Medicine, 2003
- The Neuronal Progenitor Cells of the Forebrain Subventricular Zone: Intrinsic Propertiesin Vitroand Following TransplantationMethods, 1998
- High-Affinity Binding of the Neonatal Fc Receptor to Its IgG Ligand Requires Receptor ImmobilizationBiochemistry, 1997